Pure Global
NCT06211712

Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion

Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion: A Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Study
Huashan Hospital·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Ischemic Stroke
Drug/Device/Intervention
Experimental: Human Urinary Kallidinogenase
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Huashan Hospital
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2024
End date
Dec 01, 2025
Enrollment
120 participants
Primary outcome

ASPECT score evaluated using routine CT,Modified Rankin Scale (mRS) score

Summary

The purpose of this study is to evaluate the safety and efficacy of Human Urinary
 Kallidinogenase combined with endovascular therapy in acute ischemic stroke (AIS) patients
 with large vessel occlusion.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedTransient cerebral ischaemic attack, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06211712
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06211712 through Pure Global AI's free database. This phase not specified trial is sponsored by Huashan Hospital and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.